Ross, Jennifer A. Reyes, Beverly A. S. Thomas, Steven A. and Van Bockstaele, Elisabeth J. 2017. Localization of endogenous amyloid-β to the coeruleo-cortical pathway: consequences of noradrenergic depletion. Brain Structure and Function,
Kwak, Yong Tae Yang, YoungSoon and Koo, Min-Seong 2017. Anxiety in Dementia. Dementia and Neurocognitive Disorders, Vol. 16, Issue. 2, p. 33.
Li, Xiao-Xue and Li, Zheng 2017. The impact of anxiety on the progression of mild cognitive impairment to dementia in Chinese and English data bases: a systematic review and meta-analysis. International Journal of Geriatric Psychiatry,
Fung, Ada Wai Tung and Lam, Linda Chiu Wa 2017. A cross-sectional study on clinical correlates of anxiety disorders in 613 community living older adults in Hong Kong. International Journal of Geriatric Psychiatry, Vol. 32, Issue. 7, p. 742.
Joshi, Aditi Jimenez, Elvira and Mendez, Mario F. 2017. Initial Heart Rate Reactivity to Socioemotional Pictures in Early-Onset Alzheimer’s Disease. Journal of Alzheimer's Disease, Vol. 60, Issue. 4, p. 1325.
Brown, Eric E. Iwata, Yusuke Chung, Jun Ku Gerretsen, Philip Graff-Guerrero, Ariel and Motoi, Yumiko 2016. Tau in Late-Life Depression: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, Vol. 54, Issue. 2, p. 615.
de Oliveira, Juliana Sorraila Abdalla, Fátima Husein Dornelles, Guilherme Lopes Adefegha, Stephen Adeniyi Palma, Taís Vidal Signor, Cristiane da Silva Bernardi, Jamile Baldissarelli, Jucimara Lenz, Luana Suéling Magni, Luana Pereira Rubin, Maribel Antonello Pillat, Micheli Mainardi and de Andrade, Cinthia Melazzo 2016. Berberine protects against memory impairment and anxiogenic-like behavior in rats submitted to sporadic Alzheimer’s-like dementia: Involvement of acetylcholinesterase and cell death. NeuroToxicology, Vol. 57, p. 241.
Perna, Giampaolo Iannone, Giuseppe Alciati, Alessandra and Caldirola, Daniela 2016. Are Anxiety Disorders Associated with Accelerated Aging? A Focus on Neuroprogression. Neural Plasticity, Vol. 2016, p. 1.
Babulal, Ganesh M. Ghoshal, Nupur Head, Denise Vernon, Elizabeth K. Holtzman, David M. Benzinger, Tammie L.S. Fagan, Anne M. Morris, John C. and Roe, Catherine M. 2016. Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. The American Journal of Geriatric Psychiatry, Vol. 24, Issue. 11, p. 1095.
Breitve, Monica H. Hynninen, Minna J. Brønnick, Kolbjørn Chwiszczuk, Luiza J. Auestad, Bjørn H. Aarsland, Dag and Rongve, Arvid 2016. A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer’s disease. Alzheimer's Research & Therapy, Vol. 8, Issue. 1,
Huang, Huang Nie, Sipei Cao, Min Marshall, Charles Gao, Junying Xiao, Na Hu, Gang and Xiao, Ming 2016. Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice. AGE, Vol. 38, Issue. 4, p. 303.
Mah, Linda Szabuniewicz, Claudia and Fiocco, Alexandra J. 2016. Can anxiety damage the brain?. Current Opinion in Psychiatry, Vol. 29, Issue. 1, p. 56.
Zhou, L Ma, S L Yeung, P K K Wong, Y H Tsim, K W K So, K F Lam, L C W and Chung, S K 2016. Anxiety and depression with neurogenesis defects in exchange protein directly activated by cAMP 2-deficient mice are ameliorated by a selective serotonin reuptake inhibitor, Prozac. Translational Psychiatry, Vol. 6, Issue. 9, p. e881.
Burke, Shanna L. O'Driscoll, Janice Alcide, Amary and Li, Tan 2016. Moderating risk of Alzheimer's disease through the use of anxiolytic agents. International Journal of Geriatric Psychiatry,
Xing, Yi Tang, Yi and Jia, Jianping 2015. Sex Differences in Neuropsychiatric Symptoms of Alzheimer’s Disease: The Modifying Effect of Apolipoprotein Eε4 Status. Behavioural Neurology, Vol. 2015, p. 1.
Cummings, Damian M. Liu, Wenfei Portelius, Erik Bayram, Sevinç Yasvoina, Marina Ho, Sui-Hin Smits, Hélène Ali, Shabinah S. Steinberg, Rivka Pegasiou, Chrysia-Maria James, Owain T. Matarin, Mar Richardson, Jill C. Zetterberg, Henrik Blennow, Kaj Hardy, John A. Salih, Dervis A. and Edwards, Frances A. 2015. First effects of rising amyloid-β in transgenic mouse brain: synaptic transmission and gene expression. Brain, Vol. 138, Issue. 7, p. 1992.
Bensamoun, David Guignard, Renaud Furst, Ansgar J. Derreumaux, Alexandre Manera, Valeria Darcourt, Jacques Benoit, Michel Robert, Philippe H. and David, Renaud 2015. Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People. Journal of Alzheimer's Disease, Vol. 49, Issue. 2, p. 387.
Mah, Linda Binns, Malcolm A. and Steffens, David C. 2015. Anxiety Symptoms in Amnestic Mild Cognitive Impairment Are Associated with Medial Temporal Atrophy and Predict Conversion to Alzheimer Disease. The American Journal of Geriatric Psychiatry, Vol. 23, Issue. 5, p. 466.
Weiner, Michael W. Veitch, Dallas P. Aisen, Paul S. Beckett, Laurel A. Cairns, Nigel J. Cedarbaum, Jesse Green, Robert C. Harvey, Danielle Jack, Clifford R. Jagust, William Luthman, Johan Morris, John C. Petersen, Ronald C. Saykin, Andrew J. Shaw, Leslie Shen, Li Schwarz, Adam Toga, Arthur W. and Trojanowski, John Q. 2015. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's & Dementia, Vol. 11, Issue. 6, p. e1.
Anxiety, apathy and depression are common in subjects with mild cognitive impairment (MCI) and may herald Alzheimer's disease (AD). We investigated whether these symptoms correlated with cerebrospinal fluid (CSF) markers for AD in subjects with MCI.
Subjects with MCI (n=268) were selected from the ‘Development of screening guidelines and criteria for pre-dementia Alzheimer's disease’ (DESCRIPA) and Alzheimer's Disease Neuroimaging Initiative (ADNI) studies. We measured amyloid β(1-42) protein (Aβ42) and total tau (t-tau) in CSF. Neuropsychiatric symptoms were measured with the Neuropsychiatric Inventory.
Depressive symptoms were reported by 55 subjects (21%), anxiety by 35 subjects (13%) and apathy by 49 subjects (18%). The presence of anxiety was associated with abnormal CSF Aβ42 [odds ratio (OR) 2.3, 95% confidence interval (CI) 1.6–3.3] and t-tau (OR 2.6, 95% CI 1.9–3.6) concentrations and with the combination of abnormal concentrations of both Aβ42 and t-tau (OR 3.1, 95% CI 2.0–4.7). The presence of agitation and irritability was associated with abnormal concentrations of Aβ42 (agitation: OR 1.6, 95% CI 1.1–2.3; irritability: OR 2.2, 95% CI 1.5–3.3). Symptoms of depression and apathy were not related to any of the CSF markers.
In subjects with MCI, symptoms of anxiety, agitation and irritability may reflect underlying AD pathology, whereas symptoms of depression and apathy do not.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.
Full text views reflects the number of PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
* Views captured on Cambridge Core between September 2016 - 23rd November 2017. This data will be updated every 24 hours.